CIK 0001600620
- Large accelerated filer
Aurinia Pharmaceuticals Inc.
Sign in to watch- Ticker
- AUPH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981231763
- Phone
- +1 250-744-2487
- Business address
- #140, 14315 - 118 AVENUE, EDMONTON, Alberta, Canada, T5L 4S6
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $735,889
- in 3 filings
Net −$735,889. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-02 | Huizinga Robert Bindert EVP of Research | Grant or award | +8,500 | 74,228 | ||
| 2022-03-02 | Huizinga Robert Bindert EVP of Research | Sale | −4,849 | $12.01 | $58K | 69,379 |
| 2022-03-02 | Huizinga Robert Bindert EVP of Research | Grant or award · Restricted Stock Unit | +62,448 | 62,448 | ||
| 2022-03-02 | Huizinga Robert Bindert EVP of Research | Grant or award · Stock Option (right to buy) | +106,838 | 106,838 | ||
| 2021-10-25 | Huizinga Robert Bindert EVP of Research | Option exercise | +95,000 | $3.20 | $304K | 195,728 |
| 2021-10-25 | Huizinga Robert Bindert EVP of Research | Sale | −130,000 | $29.75 | $3.9M | 65,728 |
| 2021-10-25 | Huizinga Robert Bindert EVP of Research | Option exercise · Stock Option (right to buy) | −95,000 | 3,864 | ||
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Option exercise | +16,000 | $2.63 | $42K | 122,092 |
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Option exercise | +11,136 | $3.20 | $36K | 133,228 |
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Sale | −27,136 | $24.05 | $653K | 106,092 |
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Sale | −5,364 | $23.66 | $127K | 100,728 |
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Option exercise · Stock Option (right to buy) | −16,000 | 0 | ||
| 2021-09-21 | Huizinga Robert Bindert EVP of Research | Option exercise · Stock Option (right to buy) | −11,136 | 98,864 | ||
| 2021-09-14 | Huizinga Robert Bindert EVP of Research | Sale | −22,500 | $21.75 | $489K | 106,092 |
| 2021-09-10 | Huizinga Robert Bindert EVP of Research | Sale | −5,000 | $19.83 | $99K | 133,592 |
| 2021-09-10 | Huizinga Robert Bindert EVP of Research | Sale | −5,000 | $19.76 | $99K | 128,592 |
| 2021-09-07 | Huizinga Robert Bindert EVP of Research | Sale | −5,000 | $18.30 | $92K | 138,592 |
| 2021-05-11 | Huizinga Robert Bindert Ex Vice President of Research | Option exercise | +40,000 | $3.02 | $121K | 143,592 |
| 2021-05-11 | Huizinga Robert Bindert Ex Vice President of Research | Option exercise · Stock Option (right to buy) | −40,000 | 0 |
Page 1 of 1 · 19 trades